Who am I?
My name is Dr. Nunley. I have received my undergraduate degree from Vanderbilt University in Nashville, TN, and my medical degree from the University of North Carolina School of Medicine in Chapel Hill, North Carolina. I completed my residency at the Washington University School of Medicine and completed a Health Policy Fellowship from the American Academy of Orthopaedic Surgeons in Washington, DC, as well as a fellowship in Joint Preservation, Resurfacing and Replacement at Washington University School of Medicine. I am currently the writer and supervising editor for the American Academy of Orthopedic Surgeons AAOS Now publication column titled “Ahead of the Curve”.
Beginning my Investment Journey
My journey with ROMTech began with a call from Scott. Normally I wouldn’t have picked up, or at least tell him I’m not interested. Scott had a pitch that had some buzzwords that would pique my interest, but it was when I heard his claim that the device was improving patient outcomes and satisfaction that I developed a deeper interest. Total knee replacements (TKR) are hard on the patient so this claim intrigued me. The verbiage he used enticed me to look into the company, so naturally, I googled the company and looked at their website- they were called ROM3 at the time- and when I saw Scott Wingerter listed on the board, someone I know, I decided to give him a call. After talking to him, he confirmed that this was a legitimate company with a real product that fills a need to help patients during the early physical therapy phase. There’s a real gap in the market for post-op rehab that this company seemed to be taking on and that excited me.
After deciding to invest and learning more about the efficacy and outcomes of this device, I wanted to get more involved. I didn’t want to be just an investor promoting a product I believe in. I wanted to put my money where my mouth is. I have a background in research and was able to partner with Peter (ROMTech’s CEO) to guide the development and research side of things. I not only oversee all of their clinical trials, but I now talk regularly to investors on ROMTech’s webinars to keep them up to date on research, product development and informed of the results we are seeing.
ROMTech’s outreach and marketing may seem unorthodox, but I would invite anyone with doubts about the company to reach out to anyone that is involved in ROMTech at a major medical academic center and talk to them about their experience.
My experience has been extremely positive over the last three and a half years that I’ve been working with ROMTech and collaborating with Peter. I’ve witnessed the development of the ProCycle, before it was the PortableConnect, and seen the rapid evolution of this device in such a short period of time. Something to note is that I’ve invested in other start-ups and the common issues I see are companies not able to move quickly and decisively. ROMTech can outline who they are, work swiftly through trial and error, and tackle the challenges they have, and they consistently achieve. They’ve been growing and adding more departments which my experience has been great to work with a variety of teams across the board. From the engineering team who have been completely transparent about challenges and how they are working to improve the device; from the billing and compliance teams who work with the insurance companies and legal; and their operations teams whose responsiveness to build their internal processes to be much faster and more efficient for both surgeons and patients.